Cooper, Alissa J.
Sequist, Lecia V. http://orcid.org/0000-0002-8965-6991
Lin, Jessica J. http://orcid.org/0000-0001-7373-3916
Article History
Accepted: 14 April 2022
First Online: 9 May 2022
Change Date: 15 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41571-022-00680-8
Competing interests
: L.V.S. has acted as a consultant of AstraZeneca, Genentech, Janssen, Pfizer and Takeda, and has received institutional research support from AstraZeneca, Boehringer–Ingelheim, Delfi and Novartis. J.J.L. has acted as a consultant for Bayer, Blueprint Medicines, C4 Therapeutics, Elevation Oncology, Genentech, Mirati Therapeutics, Novartis, Nuvalent and Turning Point Therapeutics, has received honoraria and travel support from Pfizer, has received institutional research funds from Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus, Neon Therapeutics, Novartis, Nuvalent, Relay Therapeutics, Roche and Turning Point Therapeutics, and has received CME funding from MedStar Health, Northwell Health and OncLive. A.J.C. declares no competing interests.